Plain-English translation of NCT06920251 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether , a preventive medication, can reduce the risk of a serious viral infection called cytomegalovirus (CMV) in patients with multiple myeloma who are receiving a new cancer treatment called elranatamab. Elranatamab is a newer type of therapy that works differently than older treatments and shows promise in helping patients live longer—but it can weaken the immune system, making serious infections more likely. This study will evaluate whether giving this medication as prevention can keep patients healthier while they receive their cancer treatment.
Elranatamab is an expensive new treatment, and when patients develop serious complications like infections, it becomes even more costly and can disrupt their care. By finding ways to prevent these infections from developing in the first place, doctors hope to help patients stay healthier, keep receiving their cancer treatment without interruption, and reduce the overall burden on healthcare systems.
You likely qualify if…
You likely don't qualify if…
You will receive the preventive medication starting in week 3 and continuing through week 16 of your cancer treatment—about four months total. During this time, you will have regular study visits to check your health, undergo blood tests to monitor for infections, and take the medication as instructed. The research team will track whether you develop any serious infections and how well the medication works as a preventive measure.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
South Korea
Phase
Testing effectiveness
Sponsor
Seoul National University Hospital
Enrollment target
~40 participants
Started
September 2025
Primary completion
December 2027
Age range
19 Years and older
Last updated on clinicaltrials.gov in December 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Ja Min Byun, MD, PhD
Seoul National University Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.